List of Biotech, Pharmaceutical & Life Sciences companies in Portugal - 12

Founded in 1924, BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 50 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world. Its strategic areas are Innovation, Internationalisation and Quality. Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. The key focus area for the Group is neurosciences. The company headquarters are located in Portugal. BIAL has also facilities in Spain, Germany, United Kingdom, Italy, Switzerland, US, Mozambique, Angola, Panama and Ivory Coast. BIAL Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA). BIAL has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award in Biomedicine, the Prémio BIAL de Medicina Clínica and Scientific Research Grants, well recognized worldwide.

Delox is a spin-off of the Faculty of Sciences of the University of Lisbon (FCUL), whose goals consist in the design of a vast portfolio of compact automatic bio-decontamination equipment. Target applications include laboratory equipment bio-decontamination, hospital rooms, as well as delivering bio-decontamination in biodefense, disaster relief and space sectors.

Immunethep is a biotech startup company that is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. We are working on preventing and treating infectious diseases to improve global health (SDG#3) for a safer tomorrow free of AntiMicrobial Resistance (AMR). We will accomplish our mission by developing anti-infective immunotherapies that potentiate a natural and strong immune response from the infected host, reducing the disease burden and mortality rates.

Lxbio Pharmaceuticals is a biopharmaceutical company based in Lisbon, Portugal, dedicated to developing innovative therapies. The company focuses on antibody and bacteriophage therapies to address unmet medical needs. Lxbio is actively involved in bacteriophage research and is a member of PhageEU, a coalition that promotes access to phage technology in the European Union. Led by experienced executives, Lxbio aims for sustainable growth and global commercialization in the biopharmaceutical market. The company's strategic vision emphasizes navigating regulatory requirements to ensure its products meet high standards. Lxbio is positioned to make a significant impact in the healthcare sector through its commitment to innovation and collaboration.

Mondego Bio is developing best-in-class Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.

Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.

Rodon Biologics is focusing in providing excellence in development of biopharmaceutical products for third parties. Over the last 20 years Rodon Biologics (previously as Biotecnol SA) has successfully completed numerous product and process development projects for different stages in the drug development cycle, from research to clinical trial Phase III. Partner led-programs have been undertaken on behalf of small, mid and large size biotechnology and also for large pharmaceutical companies. Product track record includes cytokines, growth factors, antibody fragments, immunotoxins, antibodies and multispecific antibody based formats. This continuous activity has resulted in accumulation of a significant know-how and experience with project management and a wide ranges of technologies for the development / optimization of processes and the manufacture of biological product molecules. Moreover, the intensive work on its own products pipeline also originated a new set of competencies i.e. bispecifics and highly specific analytical work. Rodon Biologics is customer-centric and innovative, in a way that customers receive products that better fit their needs, with a more complete offering in terms of services. So, in addition to full process development the new services matrix includes stand alone services (from the cloning and expression of the gene of interest, to the offering of milligrams of product for early testing, and pre-clinical toxicity batches for IND filling). Effective, robust, reliable and cost efficient manufacturing strategies are required to meet the rigorous demands of making biologics for human use. Companies need to consider their process development strategies very early in a product's lifecycle - this is where Rodon Biologics provides an invaluable service.

Sea4Us is a biotechnology company based in Sagres and Lisbon (Portugal) that specializes in the discovery and early development of new pharmaceutical drugs based on novel marine compounds. Sea4Us has developed a platform, based on marine biology and ion channels, that allows the identification of novel pharmaceutical drugs deriving from marine-living organisms for several unmet clinical needs that have ion channels as therapeutic targets. This drug discovery platform can be used to identify novel modulators for ion channels involved in different pathologies such as chronic pain, epilepsy, diabetes, cardiac arrhythmia, hypertension, and skin diseases, among others. The company's activity is focused in studying marine-living organisms' compounds bioactivities, consequent biotechnological production or artificial chemical synthesis of bioactive pure compounds, and pharmaceutical development including non-clinical and early clinical trials. The development of new pharmaceutical drugs and the improvement of the living conditions of patients is the company's main driving force. Learn more: https://lnkd.in/dUeqxv_q

SICGEN antibodies is a biotechnology company specialized in developing and production of antibodies for research in life sciences.

Launched in 2005, TechnoPhage is an innovative biopharmaceutical company committed to the R&D of new biological molecules in several therapeutic areas, such as infection, neuroscience, and ophthalmology. TechnoPhage’s strategy is based on developing new therapeutics from early discovery to clinical development, including in-house capacity for process development, and GMP production. The company has recently launched its own GMP manufacturing plant specialized in the production of biologics such as bacteriophages and antibody fragments. TechnoPhage is focused on increasing its pipeline of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across Europe, USA, and Asia. The company’s headquarters are located in Lisbon, in close proximity to the renowned Santa Maria Hospital and the Instituto de Medicina Molecular João Lobo Antunes. Overall, the proximity to these valuable partners ensures the access to the necessary equipment, and to the know-how required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.

oligosaccharide reference standards